That puts Emgality ahead of Teva’s Ajovy (fremanezumab), which picked up a positive opinion from NICE earlier this year but is only recommended for use in chronic migraine sufferers who have 15 ...

This is driven by around $200 million headwind due to loss of exclusivity for Atozet in Europe, which is expected to be offset by growth in products like Nexplanon, Vtama, Emgality, and the ...

Sales of key growth products (select products launched prior to 2022 like Cyramza, Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt and Verzenio) rose 13% to $5.95 billion.